title: PCI and clopidogrel: antiplatelet responsiveness and patient characteristics.
abstract: OBJECTIVE
  This study on responsiveness to clopidogrel and aspirin evaluates its interaction with: (i) patient characteristics; (ii) procedure characteristics; (iii) antiplatelet dose.
  
  
  RESULTS
  After elective PCI, 60 patients receiving aspirin 100 mg daily, and clopidogrel 75 mg daily were monitored with the PFA 100 test and VASP assay. Non-responsiveness to aspirin and clopidogrel was found in 23 (38%) and 18 (30%) of 60 patients, respectively. Seven (12%) patients were dual nonresponders. Non-responders to both aspirin and clopidogrel were more often smokers. Non-responders to clopidogrel, in addition had elevated inflammatory markers (P < 0.05). Dual non-responders had (i) a higher platelet count, LDL, and CRP; (ii) a lower HDL (P < 0.05). Clopidogrel non-responders were receiving 150 mg clopidogrel, with a positive response in 72%. Eighty % of non-responders to 150 mg clopidogrel were also non-responders to aspirin.
  
  
  CONCLUSIONS
  Baseline patient characteristics and clopidogrel dose modify the antiplatelet response. Also, patients resistant to both aspirin and clopidogrel do no benefit from an increased clopidogrel dose.
authors: Clinical Hospital Centre Dr Dragisa Misovic Dedinje, Belgrade, Serbia. aleksandragrdinic@yahoo.com
authors: Aleksandra
authors: A
authors: Grdinic
authors: Danilo
authors: D
authors: Vojvodic
authors: Nina
authors: N
authors: Djukanovic
authors: Mirko
authors: M
authors: Colic
authors: Aleksandar G
authors: AG
authors: Grdinic
authors: Vladimir
authors: V
authors: Ignjatovic
authors: Ivana
authors: I
authors: Majstorovic
authors: Vesna
authors: V
authors: Ilic
authors: Zvonko
authors: Z
authors: Magic
authors: Slobodan
authors: S
authors: Obradovic
authors: Miodrag
authors: M
authors: Ostojic
authors: Slavica Pavlov
authors: SP
authors: Dolijanovic
mesh_terms: D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D015815:Cell Adhesion Molecules / Q000032:analysis; D000077144:Clopidogrel; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008840:Microfilament Proteins / Q000032:analysis; D008875:Middle Aged; D009203:Myocardial Infarction / Q000517:prevention & control; D010750:Phosphoproteins / Q000032:analysis; D010865:Pilot Projects; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D010976:Platelet Count; D011446:Prospective Studies; D013927:Thrombosis / Q000517:prevention & control; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000098662:Vasodilator-Stimulated Phosphoprotein
chemical_list: D015815:Cell Adhesion Molecules; D008840:Microfilament Proteins; D010750:Phosphoproteins; D010975:Platelet Aggregation Inhibitors; D000098662:Vasodilator-Stimulated Phosphoprotein; D000077144:Clopidogrel; D013988:Ticlopidine